NCT05577312View on ClinicalTrials.gov

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

August 4, 2025

Study Completion Date

September 10, 2026

Conditions
Beta-Thalassemia
Interventions
DRUG

BRL-101

CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site

Trial Locations (4)

510510

Nanfang Hospital, Southern Medical University, Guangzhou

Xiangya Hospital of Central South University, Changsha

530021

The First Affiliated Hospital of Guangxi Medical University, Nanning

Unknown

Chinese Academy of Medical Sciences, Tianjin

Sponsors
All Listed Sponsors
collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

Chinese Academy of Medical Sciences

OTHER

collaborator

Nanfang Hospital, Southern Medical University

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT05577312 - Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia | Biotech Hunter | Biotech Hunter